| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 1.99 | 0.02 (+1.02%) | 1.71 - 6.24 | 5.0 million (Above Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 2.00 |
|---|---|
| Previous Close | 1.97 |
| Day's Range | 1.97 - 2.09 |
| Market Cap | 113.9M |
| Avg Volume (10 Day) | 1.7M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.83 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Oncothyreon Announces Data for L-BLP25 and PX-866 to be Presented at American Society of Clinical Oncology Meeting
PR Newswire - Thursday 05/16/2013 6:00 AM ET
Oncothyreon Reports First Quarter 2013 Financial Results
PR Newswire - Thursday 05/09/2013 4:05 PM ET
Mentor Capital Cancer Immunotherapy Index Gains 28% During First Quarter of 2013
Business Wire - Thursday 05/02/2013 12:19 PM ET
Oncothyreon Announces First Quarter 2013 Financial Results Conference Call
PR Newswire - Thursday 05/02/2013 8:00 AM ET
| ONTY | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|---|---|
| 6.75 | -7.66% | |
| NeoStem Inc | 0.59 | -0.08% |
| Northwest Biotherapeutics Inc | 3.71 | +1.92% |
| Agenus Inc | 4.25 | -0.23% |
| Inovio Pharmaceuticals Inc | 0.67 | +1.20% |
Data is delayed by at least 15 min.